|
News for Healthier Living
Cleveland Clinic Research Finds Injectable Medications for Obesity Produce Smaller Weight Loss in A Real-World Setting, Compared to Randomized Clinical Trials
UNDER EMBARGO UNTIL Tuesday, June 10, 2025, 3 a.m. ET, CLEVELAND: A Cleveland Clinic study shows that semaglutide and tirzepatide - injectable GLP-1 drugs for obesity - produce smaller weight loss in a real-world setting because patients discontinue treatment or use lower maintenance dosages. Treatment discontinuation also negatively impacted blood sugar control in patients with prediabetes. The study was published in the Obesity Journal.
June 10, 2025
June 14 2025June 13 2025June 12 2025June 11 2025June 10 2025June 9 2025June 8 2025June 7 2025June 6 2025June 5 2025June 4 2025June 3 2025June 2 2025June 1 2025
|
|
|
|
|